Skip to Main content Skip to Navigation
Journal articles

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.

Abstract : Objective Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income and middle-income countries, where access to nucleic acid testing remains limited. The aim of this study was to develop and validate a point-of-care (PoC) assay for the qualitative detection of HCV RNA. Design We developed a PoC assay for the qualitative detection of HCV RNA on the PCR Genedrive instrument. We validated the Genedrive HCV assay through a case–control study comparing results with those obtained with the Abbott RealTime HCV test. Results The PoC assay identified all major HCV genotypes, with a limit of detection of 2362 IU/mL (95% CI 1966 to 2788). Using 422 patients chronically infected with HCV and 503 controls negative for anti-HCV and HCV RNA, the Genedrive HCV assay showed 98.6% sensitivity (95% CI 96.9% to 99.5%) and 100% specificity (95% CI 99.3% to 100%) to detect HCV. In addition, melting peak ratiometric analysis demonstrated proof-of-principle for semiquantification of HCV. The test was further validated in a real clinical setting in a resource-limited country. Conclusion We report a rapid, simple, portable and accurate PoC molecular test for HCV, with sensitivity and specificity that fulfils the recent FIND/WHO Target Product Profile for HCV decentralised testing in low-income and middle-income countries. This Genedrive HCV assay may positively impact the continuum of HCV care from screening to cure by supporting real-time treatment decisions.
Document type :
Journal articles
Complete list of metadatas

Cited literature [17 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-01769953
Contributor : Marie-Christine Vougny <>
Submitted on : Wednesday, April 18, 2018 - 2:46:25 PM
Last modification on : Friday, October 23, 2020 - 5:03:12 PM

File

gutjnl-2017-315783.full.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

Identifiers

Citation

Alba Llibre, Yusuke Shimakawa, Estelle Mottez, Shaun Ainsworth, Tan-Phuc Buivan, et al.. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.. Gut, BMJ Publishing Group, In press, 0, pp.1-8. ⟨10.1136/gutjnl-2017-315783⟩. ⟨pasteur-01769953⟩

Share

Metrics

Record views

696

Files downloads

907